@article{cfcc64e8fbfe44d4b3d6788561ae8613,
title = "Clinician perspectives on current issues in lung cancer drug development",
abstract = "Recent advances in molecularly targeted therapy and immunotherapy offer a glimmer of hope for potentially realizing the dream of personalized therapy for lung cancer. This article highlights current questions in clinical trial design, enrollment strategies and patient focused drug development, with particular emphasis on unique issues in trials of targeted therapy and immunotherapy. Published by Elsevier Inc. on behalf of International Association for the Study of Lung Cancer.",
keywords = "Clinical trials, Immunotherapy, Lung cancer, Targeted therapy",
author = "Waqar, {Saiama N.} and Bonomi, {Philip D.} and Ramaswamy Govindan and Hirsch, {Fred R.} and Riely, {Gregory J.} and Vassiliki Papadimitrakopoulou and Dickran Kazandjian and Sean Khozin and Erin Larkins and Dickson, {Dane J.} and Shakun Malik and Leora Horn and Andrea Ferris and Shaw, {Alice T.} and J{\"a}nne, {Pasi A.} and Mok, {Tony S.K.} and Roy Herbst and Patricia Keegan and Richard Pazdur and Blumenthal, {Gideon M.}",
note = "Funding Information: Disclosure: Dr. Waqar reports grant K12 CA167540 from the NCI/NIH during the conduct of the study, and grant PI on the 1 UM1 CA186704-01 from NIH/NCI outside the submitted work. Dr. Bonomi reports serving on advisory boards of Astra Zeneca, Clovis, Merck, Biodesics, Trovagene, and Eli Lilly and on data monitoring committees of Roche Genentech and Pfizer outside the submitted work. Dr. Govindan reports consulting fees from Boehringer Ingelheim, GlaxoSmithKline, Celgene, Roche, Bayer, Genentech, Clovis, Helsinn Healthcare, and honoraria from Baxalta, and Roche outside the submitted work. Dr. Hirsch reports participation in advisory boards of Bristol-Myers Squibb, Merck, Genentech/Roche, AstraZeneca, and Lilly outside the submitted work. Dr. Riely reports personal fees from Novartis and Roche and grants from Novartis, Millennium, GlaxoSmithKline, Pfizer, Infinity Pharmaceuticals, and Ariad outside the submitted work. Dr. Papadimitrakopoulou is a scientific advisory committee member for Clovis Oncology and Genentech, reports consulting fees from Merck, AstraZeneca, Bristol-Myers Squibb, and ARIAD Pharmaceuticals and grants from the following: AstraZeneca; Bristol-Myers Squibb; the American Association for Cancer Research; the National Cancer Institute, National Institutes of Health; Cancer Prevention and Research Institute of Texas; and Hope Foundation outside the submitted work. Dr. Horn reports participation in paid advisory board for Lilly Genentech, and Merck, serving as an upaid advisory board member and steering committee member at Bristol-Myers Squibb and an upaid advisory board member at Boehringer Ingelheim, performing unpaid consulting work for Xcovery, and serving as an uncompensated steering committee member at Bayer outside the submitted work. Dr. Shaw is a consulting and scientific advisory board member for Blueprint medicine and reports consulting fees from Novartis, Genentech/Roche, Ariad, Daiich-Sankyo, Ignyta, Taiho, EMD Serono, and Pfizer outside the submitted work. Dr. J{\"a}nne reports grants and personal fees from AstraZeneca; consulting fees from Boehringer Ingelheim, Pfizer, Merrimack Pharmaceuticals, Chugai, and Roche; grants from Astellas; consulting fees from Ariad; and stock ownership in Gatekeeper Pharmaceuticals during the conduct of the study. In addition, Dr. J{\"a}nne receives postmarketing royalties from Dana-Farber Cancer Institute–owned intellectual property on epidermal growth factor receptor mutations licensed to Lab Corp. Dr. Mok reports personal fees from AstraZeneca, Roche/Genentech, Pfizer, Lilly, Boehringer Ingelheim, Merck Serono, Merck Sharp and Dohme, Janssen, Clovis Oncology, BioMarin, GlaxoSmithKline, Novartis, SFJ Pharmaceuticals, ACEA Biosciences, Vertex Pharmaceuticals, Bristol-Myers Squibb, AVEO and Biodesix, Prime Oncology, Amgen, Sanomics Ltd., and geneDecode outside the submitted work. Dr. Herbst reports personal fees from Diatech, Kolltan, AstraZeneca, Boehringer Ingelheim, Eli Lilly, and Pfizer and grants and personal fees from Genentech/Roche and Merck outside the submitted work. The remaining authors declare no conflict of interest. Publisher Copyright: {\textcopyright} 2016 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.",
year = "2016",
doi = "10.1016/j.jtho.2016.05.009",
language = "English",
volume = "11",
pages = "1387--1396",
journal = "Journal of Thoracic Oncology",
issn = "1556-0864",
number = "9",
}